Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
Taiwan News

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Multiple Sclerosis News Today

Ocrevus and Tysabri appear to work equally well to control relapsing MS

Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.
Healio

Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Monthly Prescribing Reference

High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
Multiple Sclerosis News Today

New real-world study supports long-term Ocrevus use in relapsing MS

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
Monthly Prescribing Reference

Briumvi Approved for Relapsing Forms of Multiple Sclerosis

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...
Medscape

NICE Recommends Ublituximab for Relapsing MS in Adults

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
Healio

EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis

Please provide your email address to receive an email when new articles are posted on . Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside ...
Las Vegas Review-Journal

A little inspiration can go a long way for people living with relapsing multiple sclerosis

(BPT) - Visit MSInspiration.com for a chance to win a day of inspiration! At first glance, Marci Viland and Chris Wright don’t have very much in common. Their paths have never crossed, they live in ...
Everyday Health

FDA Approves Briumvi to Treat Relapsing Multiple Sclerosis

On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, ...